Share on StockTwits

Exelixis (NASDAQ:EXEL) announced its earnings results on Thursday. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.39) by $0.01, AmericanBankingNews.com reports. The company had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.66 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. The company’s quarterly revenue was down 44.7% on a year-over-year basis.

Exelixis (NASDAQ:EXEL) traded down 5.62% on Thursday, hitting $4.03. 5,026,146 shares of the company’s stock traded hands. Exelixis has a 52-week low of $3.02 and a 52-week high of $8.41. The stock has a 50-day moving average of $3.65 and a 200-day moving average of $4.8. The company’s market cap is $784.6 million.

EXEL has been the subject of a number of recent research reports. Analysts at Leerink Swann reiterated a “market perform” rating on shares of Exelixis in a research note on Friday, May 2nd. They now have a $4.50 price target on the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of Exelixis in a research note on Friday, May 2nd. They now have a $4.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $6.70.

Exelixis, Inc (NASDAQ:EXEL) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.